09th week of 2009 patent applcation highlights part 37 |
Patent application number | Title | Published |
20090053178 | USE OF HERPES VECTORS FOR TUMOR THERAPY - Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells. According to the latter approach, both the first HSV and the second HSV may have genomes that comprise, respectively, an expressible nucleotide sequence coding for at least one immune modulator. In another embodiment, the pharmaceutical composition comprises, in addition to a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells, a viral vector comprising at least one expressible nucleotide sequence coding for at least one immune modulator. | 2009-02-26 |
20090053179 | METHOD FOR USING LIBERATED DORMANT BACTERIOPHAGE AND ENVIRONMENTAL STRESS TO REDUCE INFECTIOUS BACTERIA - A method for obtaining bacteriophages by stressing bacteria. The method involves isolating bacteria, propagating the bacteria, exposing the bacteria to at least one environmental stressing agent to induce excision of bacteriophage that are present in the bacterial genome. Multiple or individual environmental stressing agents may be applied. These liberated bacteriophages may be collected for purposes of treating pathogenic infections, protecting plants and agricultural products or general sterilization and sanitation. | 2009-02-26 |
20090053180 | Tandem cardiac pacemaker system - This invention provides pacemaker systems comprising (1) an electronic pacemaker, and (2) a biological pacemaker, wherein the biological pacemaker comprises a cell that functionally expresses a chimeric hyperpolarization-activated, cyclic nucleotide-gated (HCN) ion channel at a level effective to induce pacemaker current in the cell. The invention also provides related biological pacemakers, atrioventricular bridges, methods of making same, and methods of treating a subject afflicted with a cardiac rhythm disorder. | 2009-02-26 |
20090053181 | Modulation of Cells - The present invention is directed to methods which can be used to test agents for their ability | 2009-02-26 |
20090053182 | ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME - The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium. | 2009-02-26 |
20090053183 | Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 2009-02-26 |
20090053184 | COMPOSITIONS COMPRISING T CELL RECEPTORS AND METHODS OF USE THEREOF - Nucleic acids encoding antitumor TCRs recognizing MART-1, NY-ESO-1, and melanoma gp100 peptides; vectors and cells comprising the same; and methods of using the foregoing. | 2009-02-26 |
20090053185 | Coagulation factor x polypeptides with modified activation properties - The present invention relates to modified cDNA sequences coding for human Factor X and their derivatives with improved stability and modified activation sequences, recombinant expression vectors containing such cDNA sequences, and host cells transformed with such recombinant expression vectors. The invention also relates to recombinant factor X polypeptides and derivatives which have biological activities of the unmodified wild type protein but with improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA. | 2009-02-26 |
20090053186 | Therapy for primary and metastatic cancers - The present invention relates to compositions and methods for ablating tumor cells in a subject having at least one tumor site. More specifically, the method comprises contacting the tumor cells in at least one tumor with a lytic agent in vivo, under lytic conditions, forming a treated tumor; and applying a sufficient in vivo stimulus to the treated tumor forming a stimulated tumor. Compositions and methods are included for shrinking a local tumor or a distal metastatic tumor, or both in a subject. In a preferred embodiment, the method for shrinking a tumor in a subject comprises: contacting a stimulated tumor cells in vivo with a lytic agent. The stimulus directed toward the tumor cells is capable of increasing the level of chaperone proteins in the tumor cells. The combination of lytic agents and tumor cell stimulus leads to shrinkage of the tumors that were treated directly, wherein the stimulus is either applied simultaneously or sequentially. Moreover, distal or metastatic tumors that were not-treated directly are also decreased by introducing a lytic agents into a stimulated tumor cells in a first-tumor (“the treated tumor” or “the local tumor”). The preferred method steps that include introduction of a lytic agent and stimulation of the tumor cells is repeated in order to maximize the tumor shrinkage effects. | 2009-02-26 |
20090053187 | Agent exhibiting bactericidal action with respect to vegetative and spore cells bacillus anthrasis, anthrax preventing and treating method - The invention relates to the field of biotechnology, medicine, and veterinary and can be used for anthrax prevention and treatment. The proposed drug has a bactericidal effect on vegetative and spore cells of | 2009-02-26 |
20090053188 | METHOD OF PREVENTING REDUCED FEED INTAKE IN ANIMALS AND TREATMENT OF DISEASE CONDITIONS - The present invention relates to a method for substantially preventing a reduction in feed intake in an animal which occurs when said animal is administered an antibiotic, the method comprising administering to an animal in need of prevention of a reduction in feed intake, increasing doses of a composition comprising one or more antibiotics. The present invention also relates to a method for treating laminitis and fermentative acidosis in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics. The present invention further relates to a method for treating equine grass sickness and pulpy kidney in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics. | 2009-02-26 |
20090053189 | Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof - The present invention is based, at least in part, on the identification of molecules involved in the differentiation and/or activity of osteoblasts and osteoclasts. Accordingly, the present invention provides methods of identifying modulators of bone formation, mineralization, and/or osteoclastogenesis and methods for treating disorders that would benefit from modulation of bone formation, mineralization, and/or osteoclastogenesis using agents identified as described herein. | 2009-02-26 |
20090053190 | Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions - The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from | 2009-02-26 |
20090053191 | PHOSPHOLIPASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided. | 2009-02-26 |
20090053192 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF - Disclosed herein are tissue-nonspecific alkaline phosphatase (TNAP) activators and uses thereof for promoting bone mineral deposition. | 2009-02-26 |
20090053193 | Use of Factor VIIa for the Treatment of Burn Trauma - The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of burn trauma. | 2009-02-26 |
20090053194 | METHOD OF TREATING OR PREVENTING BIOLOGICAL OR IMMUNOLOGICAL RESPONSES TO A REACTIVE CHEMICAL OR BIOLOGICAL OR TOXIC AGENT - A method of treatment for treating, preventing, inhibiting or reducing a biological or immunological response to a reactive chemical agent, biological agent or toxin, by tissue of a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a response-inhibiting agent including amino acid sequence LKKTET [SEQ ID NO: 1], a conservative variant thereof, or an agent that stimulates production of an LKKTET [SEQ ID NO: 1] peptide, or a conservative variant thereof, in the tissue, so as to inhibit the response. | 2009-02-26 |
20090053195 | BIOMARKERS FOR ACUTE GRAFT REJECTION - Methods are disclosed for the early non-invasive diagnosing of acute rejection (AR) in a transplanted subject, monitoring AR in a transplanted subject at risk of developing AR, preventing, inhibiting, reducing or treating AR in a transplanted subject, or identifying agents for use in the prevention, inhibition, reduction or treatment of AR, based on genes which are differentially expressed in peripheral blood or transplant biopsy tissues, before full clinical manifestation of AR is detected in the transplanted subject. | 2009-02-26 |
20090053196 | Chn-1/Chip-Antagonists For The Treatment Of Muscular Diseases - The present invention relates to a pharmaceutical composition comprising an inhibitor/negative regulator/antagonist of the mammalian ortholog of | 2009-02-26 |
20090053197 | Transfer Factor Compositions and Methods - Compositions are provided comprising transfer factor alone or combined with an antibody. The antibody may be contained in an antibody fraction. The transfer factor and/or the antibody or antibody fraction may be lyophilized. Also provided are formulations further comprising glucans, as well as additional optional components. Also provided are methods for making the compositions and formulations, as well as kits containing the compositions. Methods of preventing and/or treating a condition in a subject using the compositions and/or formulations are also provided. Such conditions may include malignant and benign tumors. | 2009-02-26 |
20090053198 | Cytokine Induction of Selectin Ligands on Cells - Methods and compositions for treating cells with cytokines are provided herein. | 2009-02-26 |
20090053199 | Stable Dairy Components Effective for Fat Loss - The present invention relates to methods comprising administering to individuals regulating body weight calcium-containing fresh whey products in an amount effective to manage body mass, by inducing weight and/or fat loss, preventing weight and/or fat gain, increasing the metabolic consumption of adipose tissue, and/or maintaining muscle mass. | 2009-02-26 |
20090053200 | Method for retarding unhealth manifestations brought by ageing of human beings - It is an object of the present invention to provide a solution for creating an effective method for retarding unhealthy manifestations brought by ageing of human beings (in particular, but not limited to the reduction of sexual activity and fertility, climax, changes in glucose tolerance, reduction of cognitive and mnestic functions, reduction of stress resistance, development of organ and tissue sclerosis) without directly affecting the genetic apparatus of the ageing cells. | 2009-02-26 |
20090053201 | HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus. | 2009-02-26 |
20090053202 | Peptide fragment of LYVE-1 and antibody against the same - It is intended to provide a specific peptide fragment of LYVE-1 which can serve as an epitope of a lymphatic vessel-specific antibody, and an antibody recognizing the above peptide fragment. A peptide fragment comprising an amino acid sequence:
| 2009-02-26 |
20090053203 | Metal-binding therapeutic peptides - The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes. | 2009-02-26 |
20090053204 | Functional Genomic Pore Assay For Mixed Cell Populations - A method of assaying nucleotide receptor P2X | 2009-02-26 |
20090053205 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS - The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8. | 2009-02-26 |
20090053206 | NOVEL SYNTHETIC AGONISTS OF TLR9 - The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles. | 2009-02-26 |
20090053208 | Methods and Systems for Improving Tissue Perfusion - Methods and systems are disclosed for treating injured and/or ischemic tissue by delivering a platelet composition which induces neovascularization in the tissue and improves tissue perfusion. | 2009-02-26 |
20090053209 | Blockade of Pin1 Prevents Cytokine Production by Activated Immune Cells - The invention provides pharmaceutical compositions and methods of treating immunological disorders. The invention also provides pharmaceutical compositions and methods of inducing eosinophil apoptosis, and methods for treating eosinophil-associated disorders comprising inducing eosinophil apoptosis in an individual in need thereof. | 2009-02-26 |
20090053210 | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals - The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Igα and/or Igβ sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Igα and/or Igβ results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies. | 2009-02-26 |
20090053211 | Optimized Fc variants - The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 2009-02-26 |
20090053212 | HUMANIZED ANTI-HUMAN OSTEOPONTIN ANTIBODY - The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies. | 2009-02-26 |
20090053213 | Anti-Gm-Csf Antibodies and Uses Therefor - The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 2009-02-26 |
20090053214 | Humanised Anti-MAG Antibody or Functional Fragment Thereof - The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. | 2009-02-26 |
20090053215 | Cytotoxicity mediation of cells evidencing surface expression of CD63 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention. | 2009-02-26 |
20090053216 | Treatment with Anti-VEGF Antibodies - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2009-02-26 |
20090053217 | Human anti-VEGF polyclonal antibodies and uses thereof - This invention relates to IVIG and fragments thereof and their use, specifically, provided herein are compositions and methods of inhibiting VEGF or VEGF receptor using polyclonal antibodies (pAb), or fragments thereof derived from human immunoglobulins. | 2009-02-26 |
20090053218 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. | 2009-02-26 |
20090053219 | METHODS AND COMPOSITIONS FOR INCREASING ALPHA-L-IDURONIDASE ACTIVITY IN THE CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in α-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an α-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-α-L-Iduronidase fusion antibodies as described herein. | 2009-02-26 |
20090053220 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF HIV INFECTION OF T CELLS - The present invention is based upon the surprising discovery that exposure of a non-resistant HIV to a first entry inhibitor, such as an anti-CD4 antibody or a co-receptor inhibitor, which like all current HIV drugs selects for mutations that result in a resistant HIV, surprisingly results in HIV viruses much more susceptible to neutralization by a second entry inhibitor, such as soluble CD4 (sCD4) or an HIV gp41 inhibitor. Therefore, the present invention provides methods and compositions for inhibiting HIV-1 infection in a subject that overcomes the problem of drug resistance. | 2009-02-26 |
20090053221 | IMMUNE RESPONSE ENHANCING GLUCAN - This invention discloses a composition for enhancing the protective immunity in a subject, comprising an effective amount of a β-glucan and a vaccine, wherein the β-glucan enhances the immune response of the vaccine against cancer or infectious agents. The infectious agents can be viruses, fungi, bacteria or parasites. In one embodiment, the β-glucan is derived from yeast and comprises side chains attached to a β-(1,3) backbone. In another embodiment, the vaccine comprises an antibody and whole tumor cells. The invention also provides a method of enhancing protective immunity using said composition. | 2009-02-26 |
20090053222 | Methods of Treating Cancer by Administering Antibodies to CD200 - Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth. | 2009-02-26 |
20090053223 | EXPRESSION-ENHANCED POLYPEPTIDES - A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety. | 2009-02-26 |
20090053224 | LOX AND LOXL2 INHIBITORS AND USES THEREOF - The present application relates to anti-LOX and anti-LOXL | 2009-02-26 |
20090053225 | Recombinant antibodies against cd55 and cd59 and uses thereof - The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20. | 2009-02-26 |
20090053226 | Compositions and methods for the treatment of tumor of hematopoietic origin - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2009-02-26 |
20090053227 | Prostate Specific Genes and The Use Thereof in Design of Therapeutics - Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer. A preferred target gene is Kv3.2. | 2009-02-26 |
20090053228 | Lawsonia intracellularis subunit vaccines - The present invention relates i.a. to nucleic acids encoding novel | 2009-02-26 |
20090053229 | Methods of Treating Conditions Involving Neuronal Degeneration - The invention provides methods for treating conditions of the eye involving death or degeneration of retinal ganglion cells, including glaucoma, by the administration of Nogo receptor-1 antagonists. | 2009-02-26 |
20090053230 | ANTI-OX40L ANTIBODIES AND METHODS USING SAME - The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies. | 2009-02-26 |
20090053231 | Optical Disc Apparatus - Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders. | 2009-02-26 |
20090053232 | MODULATION OF SYNAPTOGENESIS - The present invention describes methods and compositions for modulating synaptogenesis and axon and/or dendritic growth. The methods include the use of agents that modulate a thrombospondin and/or an α2δ subunit of a calcium channel. | 2009-02-26 |
20090053233 | Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations - The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of FcγRIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma. | 2009-02-26 |
20090053234 | Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents - The present invention provides to methods of preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder comprising administering to a subject in need thereof one or more integrin α | 2009-02-26 |
20090053235 | Use of alpha-toxin for treating and preventing staphylococcus infections - Vaccines comprising an | 2009-02-26 |
20090053236 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR - The object of the present invention is to find a pharmaceutical composition and a method for treating cancer that show an excellent antitumor effect. Combinational use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and analogues thereof can result in an excellent antitumor effect when combined with a substance having a c-kit kinase-inhibiting activity. | 2009-02-26 |
20090053237 | USE OF PENICILLIN-BINDING PROTEINS OR POLYNUCLEOTIDES OR ANTIBODIES THEREOF FOR PREVENTING OR TREATING BACTERIAL INFECTIONS - The present invention is drawn to a penicillin-binding protein expressed by | 2009-02-26 |
20090053238 | Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations - The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin α | 2009-02-26 |
20090053239 | ACACS As Modifiers of the IGF Pathway and Methods of Use - Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided. | 2009-02-26 |
20090053240 | Novel Immunoglobulin Insertions, Deletions and Substitutions - An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide. | 2009-02-26 |
20090053241 | PDGFRbeta-specific inhibitors - The invention is directed to novel PDGFRβ-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFRβ-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs. | 2009-02-26 |
20090053242 | Thrombopoietic compounds - The invention relates to the use of compounds, especially peptides or polypeptides, that have thrombopoietic activity, and pegylated forms thereof. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal. | 2009-02-26 |
20090053243 | Anti-IgSF4 Antibody and Utilization of the Same - It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc. | 2009-02-26 |
20090053244 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods - Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The viruses also can be used in diagnostic methods. | 2009-02-26 |
20090053245 | Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood - A method for modulating at least one pharmacokinetic property of an anti-angiogenic or blood disease or steroid therapeutic and efficacy upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the anti-angiogenic or blood disease or steroid therapeutic or an active derivative thereof and a pharmacokinetic modulating moiety. The pharmacokinetic modulating moiety binds to at least one intracellular protein. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host as compared to a free drug control that comprises the anticancer therapeutic as well as enhanced efficacy not due to compound degradation. It is preferred that the pharmacokinetic modulating moiety has a mass of less than 1100 Daltons. | 2009-02-26 |
20090053246 | IMMUNOGLOBULIN FC FRAGMENT MODIFIED BY NON-PEPTIDE POLYMER AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by a non-peptide peptide according to the present invention lacks immunogenicity and effector functions. Due to these properties, the Fc fragment maintains the in vivo activity of a drug conjugated thereto in high levels, remarkably increases the serum half-life of the drug, and remarkably reduces the risk of inducing immune responses. | 2009-02-26 |
20090053247 | BIOLOGICAL MATERIALS AND USES THEREOF | 2009-02-26 |
20090053248 | Compositions and methods for transepithelial molecular transport - The invention relates to fragments of | 2009-02-26 |
20090053249 | Specific Inhibition of Autoimmunity and Diseases Associated With Autoantigens - The present invention provides compositions and methods for specifically inhibiting host immune responses against autoantigens. In particular, compositions and methods combining CD8 polypeptide expression with autoantigen expression or presentation are described for specifically inhibiting the humoral and cellular components of the host immune response to autoantigens. | 2009-02-26 |
20090053250 | Immune Modulating Oligonucleotides in Connection with Chemotherapeutic Measures - The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs. | 2009-02-26 |
20090053251 | Dendritic Cell Compositions and Methods - Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1° C.-34° C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells. | 2009-02-26 |
20090053252 | BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUATROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. | 2009-02-26 |
20090053253 | Process for the measurement of the potency of glatiramer acetate - The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use. | 2009-02-26 |
20090053254 | RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS AN IMMUNOSUPPRESSIVE AGENT - Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof. | 2009-02-26 |
20090053255 | Anti-arthropod vector vaccines, methods of selecting and uses thereof - The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis. | 2009-02-26 |
20090053256 | Poxvirus Methods And Compositions - Methods and compositions for inducing immune responses against poxviruses are disclosed. The compositions include nucleic acids that encode modified vaccinia and variola antigens. Compositions that include recombinant vaccinia and variola polypeptides are also disclosed. | 2009-02-26 |
20090053257 | REPLIKIN PEPTIDES AND USES THEREOF - The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease. | 2009-02-26 |
20090053258 | Assays for diagnosis of tuberculosis and uses thereof - The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines. | 2009-02-26 |
20090053259 | VACCINES AND METHODS FOR TREATMENT OR PREVENTION OF GRAM NEGATIVE BACTERIAL INFECTION IN A VERTEBRATE SUBJECT - Methods for the treatment or prevention of Gram negative bacterial infection in a vertebrate subject are provided. The methods provide administering an antagonist of bacterial flagellar protein biosynthesis to the vertebrate subject in an amount effective to reduce or eliminate the bacterial infection. Methods for the treatment or prevention of | 2009-02-26 |
20090053260 | ALGAE ESSENCE NUCLEIC ACID FLUID CONCENTRATION PREPARATION METHOD - The present invention discloses an alga essence nucleic acid fluid concentration method, to apply the leaching function principle with the operation of freezes defreeze to achieve the goal of extract nucleic acid from the concentrated | 2009-02-26 |
20090053261 | Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications - Display of peptides or proteins in an ordered, repetitive array, such as on the surface of a virus-like particle, is known to induce an enhanced immune response relative to vaccination with the “free” protein antigen. The 2100 coat proteins comprising the rod-shaped capsid of Tobacco mosaic virus (TMV) can accommodate short peptide insertions into the primary sequence, but the display of larger protein moieties on the virion surface by genetic fusions to the capsid protein has not been possible. Since TMV lacks surface exposed residues compatible with commonly available linker chemistries, we employed a randomized library approach to introduce a reactive lysine at the externally located at the amino-terminus of the coat protein. We found that we could easily control the extent of virion conjugation and demonstrated stoichiometric biotinylation of the introduced lysine. To characterize this modular platform for the display of heterologous proteins, we bound a model antigen (streptavidin (SA)-green fluorescent protein (GFP), expressed and purified from plants) to the surface of TMV, creating a GFP-SA decorated virus particle. Rapid and quantitative determination of the level of TMV capsid decoration was accomplished by subjecting the complex to amino acid analysis and solving the family of linear equations relating the pmoles of each residue to the known amino acid composition of the complex components. We obtained a GFP-SA tetramer loading of 26%, which corresponds to display of approximately 2200 GFP moieties per intact virion. We evaluated the immunogenicity of GFP decorated virions in both mice and guinea pigs, and found augmented humoral IgG titers in both species, relative to unbound GFP-SA tetramer. In mice, we observed a detectable humoral immune response after only a single immunization with the TMV-protein complex. By demonstrating the presentation of whole proteins, this study expands the utility of TMV as a vaccine scaffold beyond that which is possible by genetic manipulation. | 2009-02-26 |
20090053262 | Combination vaccine for poultry - The present invention relates to a combination vaccine for the protection of poultry against | 2009-02-26 |
20090053263 | Inhibitors of Enveloped Virus Infectivity - The present invention relates to treatment of infection by enveloped viruses through the use of papain-like cysteine protease inhibitors and kits thereof. Specifically, methods for treatment of filoviruses as well as other enveloped viruses such as Nipah, in particular using cathepsin inhibitors are described. | 2009-02-26 |
20090053264 | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals - The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. | 2009-02-26 |
20090053265 | Antigenic peptides and their use - This invention relates generally to the field of pathogen peptidic antigens and their use, for example, for the preparation of a vaccine against said pathogen. More specifically, the present invention relates to an antigenic peptide deriving from | 2009-02-26 |
20090053266 | Apicomplex vaccine strains of a family of sarcocystidae - The invention relates to attenuate mutated strains of apicomplex of a family of Sarcocystidae, containing inactivated MIC | 2009-02-26 |
20090053267 | DENTIFRICE COMPOSITION CONTAINING SILICONE OIL BEADS - Dentifrice composition and method of using such dentifrice composition to ameliorate dry mouth, where the dentifrice composition includes an orally acceptable vehicle having distributed therein silicone oil beads, and wherein the dentifrice composition has a viscosity of at least about 20,000 centipoise. | 2009-02-26 |
20090053268 | NANOPARTICLE MODIFIED LUBRICANTS AND WAXES WITH ENHANCED PROPERTIES - The present invention provides compositions and products, such as waxes and lubricants, comprising a plurality of nanoparticles dispersed in a continuous phase comprising a vegetable oil derived material, such as one or more vegetable oils or a synthetic product derived from one or more vegetable oils. Incorporation of nanoparticles in the present compositions is beneficial for providing mechanical, thermal and/or chemical properties useful for a selected product or product application. In some compositions of the present invention, for example, incorporation of the nanoparticle component provides compositions derived from one or more vegetable oils exhibiting enhanced mechanical stability, hardness, viscosity, thermal stability and mechanical strength. | 2009-02-26 |
20090053269 | Powder-Containing Transparent Solid Cosmetic Preparation - The present invention provides a novel solid powder which has transparency in its appearance, and has excellent usability and, in addition, excellent feeling of use such as dry feeling and fresh light feeling without sticky feeling during application. It is achieved by a solid powder cosmetic comprising: (A) 25 to 55% by mass of elastic powder mixture; (B) 20 to 40% by mass of non-elastic spherical silicone resin powder with an average particle diameter within the range of 0.1 to 50 μm; and (C) 25 to 55% by mass of oil, as essential components, wherein (A) the elastic powder mixture comprises one or more types of each (A1) an elastic powder and (A2) a composite powder obtained by coating the periphery of an elastic powder with a non-elastic material, said solid powder cosmetic being obtained by caking a mixed composition of these essential components. | 2009-02-26 |
20090053270 | COSMETIC FOR EYELASHES - The cosmetic for eyelashes according to the present invention is capable of simply imparting a good curl-up effect to eyelashes, is free from formation of lumps upon coating, and can exhibit a high moisture resistance and a high curl retention effect during use as well as a beautiful finish. The present invention relates to a cosmetic for eyelashes which includes a film-forming polymer (A) containing constitutional units derived from methacrylic acid and/or a salt thereof (monomer (a)) and a monomer (b) having a solubility of 2 g or less in 100 g of water as measured at 20° C., and having a glass transition temperature (Tg | 2009-02-26 |
20090053271 | Reverse-Phase Microcapsules for Actice Ingredients, Simplified Process of Manufacture Thereof and Combined Formulation Wdg- Cs,Zc, Ec-Sc, and Cx - This invention relates to microcapsules and processes of microencapsulation of water soluble or water dispersible compounds by reverse-phase microencapsulation, referred to agrochemicals but not as a limiting feature, and how to combine them with other oil soluble or oil dispersible compounds in suitable formulations for agriculture, in a industrially viable process that yields tiny microcapsules (<5-10 μm, preferably) and very homogeneous distribution of particle size, and overall good performance of the formulation. Further, multiple combinations of this reverse-phase microcapsules are disclosed, being specially notorious the combination with normal-phase microcapsules in order to create a Capsule Mixed Suspension (CX) where an outer oil—or alternatively water—phase contains microcapsules of two types: those with a core of water—and actives dissolved or dispersed therein—and those with a core of oil—and actives dissolved or dispersed therein—. Water Dispersable Granules (WDG) and Emulsion Concentrates (EC) and suspension concentrates (SC) combinations with the reverse phase microcapsules are also successfully performed, providing a novel concept of combinations of oil soluble with water soluble microencapsulated active ingredients. | 2009-02-26 |
20090053272 | METHOD FOR PRODUCING POLYMER NANOPARTICLES - A process for the preparation of polymeric nanoparticles, in which an emulsion of monomers and additional components is produced in a nonsolvent and subsequently illuminated, makes it possible to prepare polymeric nanoparticles which comprise, in a desired concentration, an effect substance, for example a dye, and/or an active substance, for example a herbicide. | 2009-02-26 |
20090053273 | Topical medication garment and system and method for providing topical medication - A topical medication garment, a system and a method provide topical medication. An impermeable garment may allow the topical medication to maintain contact with the skin of the user. The garment may prevent the topical medication from absorption into clothing or the undergarment itself. The entirety of the garment may be made from an impermeable material or a portion of the garment may be made from an impermeable material. An impermeable liner may be attached to and/or may be connected to an interior surface of the garment. The garment may have legging portions that reside on the upper thighs of the user when the garment is worn. The legging portions may secure the position of the garment on the user and providing coverage of topical medication applied to the crotch area and upper thighs. The garment may have a structure that resembles a t-shirt. | 2009-02-26 |
20090053274 | DELIVERY SYSTEM FOR A MEDICAMENT OR WELL-BEING ENHANCING COMPOSITION - A delivery system for a medicament or well-being enhancing composition, comprising a flexible member, means for attaching the flexible member to fabric to form a pocket and an absorbent pad for impregnation with the medicament or well-being enhancing composition arranged such that when the flexible member is attached to a piece of fabric a pocket is formed shaped and sized such the pad may be received and held securely within the pocket but is removable therefrom. The fabric is typically part of a garment or bed-linen. | 2009-02-26 |
20090053275 | Foam/spray producing compositions and dispencing system therefor - By providing a therapeutic agent in a mixture with water in combination with at least one selected from the group consisting of surfactants, excipients, thickening agents, and water, a unique, improved, liquid based foam or spray and/or gel producing formulation is realized which is useable for a wide variety of applications. In the preferred embodiment, the improved formulations incorporate one or more therapeutic agents which comprise a silver-based composition. As a result, the formulation is useable for a wide variety of medical applications for preventing, treating, or reducing the spread or transmission of bacteria, virus, infections, and the like. | 2009-02-26 |
20090053276 | INJECTABLE HYDROGEL COMPOSITIONS - In accordance with one aspect of the invention, injectable compositions are provided, which contain temperature-sensitive hydrogel particles. The hydrogel particles may be provided in dry form, or they may be provided in hydrated form in an aqueous fluid. The temperature-sensitive hydrogel particles may have an upper critical solution temperature (UCST) below normal body temperature, they may have a lower critical solution temperature (LCST) above normal body temperature, or they may have a LCST that changes from below normal body temperature to above normal body temperature after injection into a subject. | 2009-02-26 |
20090053277 | Cell Sheet Containing Mesenchymal Stem Cells - Mesenchymal stem cells are pluripotent cells capable of differentiating into myocardial and vascular endothelial cells. The present invention demonstrates that the mesenchymal stem cell sheet have therapeutic potential for a severely damaged heart due to its pluripotency and in situ self-renewal capability. Mesenchymal stem cells derived from adipose tissue were cultured to prepare a mesenchymal stem cell sheet. Four weeks after induction of myocardial infarction in rats, the mesenchymal stem cell sheet was transplanted to the heart. The mesenchymal stem cell sheet were readily engrafted to the surface of the scarred myocardium, grew gradually in situ, and formed a thick layer (approximately 600 μm) in 4 weeks. The grown transplanted mesenchymal tissue contained newly formed blood vessels, myocardial cells, and undifferentiated mesenchymal cells. The engrafted mesenchymal stem cells inhibited thinning of the myocardial wall in the scar area, and improved cardiac function and survival rate in rats with myocardial infarcts. Thus, mesenchymal stem cell sheet transplantation may represent a novel therapeutic approach for myocardial tissue regeneration. | 2009-02-26 |
20090053278 | ANTI-MICROBIAL COMPOSITIONS AND DEVICES AND METHODS OF USING THE SAME - Embodiments of the present invention include medical devices that are coated with an antimicrobial peptide-based coating. Further embodiments include methods of coating the devices with the antimicrobial peptide-based coating, and treating a subject with the coated medical devices to prevent or relieve bacterial infections in the subject. | 2009-02-26 |